This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why
by Zacks Equity Research
Erytech Pharma SA Sponsored ADR (ERYP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%
by Zacks Equity Research
After evaluating the FDA's feedback, Erytech Pharma (ERYP) halts developing its lead candidate in leukemia. It is also looking for strategic partnerships to leverage its proprietary platform.
Company News for Dec 1, 2021
by Zacks Equity Research
Companies in the news are: CHS, CTRN, IMGN, ERYP
ERYTECH Pharma (ERYP) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
ERYTECH Pharma S.A. (ERYP) has been struggling lately, but the selling pressure may be coming to an end soon
ERYTECH Pharma (ERYP) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
ERYTECH Pharma (ERYP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Athersys (ATHX) Surges: Stock Moves 8.8% Higher
by Zacks Equity Research
Athersys (ATHX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Erytech Pharma SA Sponsored ADR (ERYP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will ERYTECH Pharma Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor ERYTECH Pharma.
Erytech Pharma Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Erytech Pharma SA (ERYP) has been struggling lately, but the selling pressure may be coming to an end soon.
Moving Average Crossover Alert: Erytech Pharma
by Zacks Equity Research
Erytech Pharma is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Erytech Pharma Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Erytech Pharma has been struggling lately, but the selling pressure may be coming to an end soon.
6 European Stocks to Shun on Tapered IMF Outlook
by Sanghamitra Saha
IMF lowered its growth projection for in Germany, France and Italy. Time to avoid these sell-ranked stocks?